Skip to main content
Gulam Manji, MD, Oncology, New York, NY

GulamAbbasManjiMDPhD

Oncology New York, NY

Gastrointestinal Cancer, Hematologic Oncology, Sarcoma

Assistant Professor

Overview of Dr. Manji

Dr. Gulam Manji is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Ross University School of Medicine and has been in practice 8 years. He is one of 375 doctors at New York-Presbyterian Hospital and one of 119 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 40 publications and over 500 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2012 - 2015
  • Albany Medical Center
    Albany Medical CenterResidency, Internal Medicine, 2009 - 2012
  • Ross University School of Medicine
    Ross University School of MedicineClass of 2009

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2024 - 2026
  • NY State Medical License
    NY State Medical License 2012 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral ... 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Researchers Discover How Pancreatic Cancer Cells Evade Starvation
    Researchers Discover How Pancreatic Cancer Cells Evade StarvationNovember 3rd, 2020
  • BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
    BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic CancerOctober 29th, 2020
  • BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
    BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)February 29th, 2024
  • Join now to see all